Response to recombinant erythropoietin alpha, without the adjunct of granulocyte-colony stimulating factor, is associated with a longer survival in patients with transfusion-dependent myelodysplastic syndromes

Pellegrino Musto, Oreste Villani, Maria Carmen Martorelli, Giuseppe Pietrantuono, Roberto Guariglia, Giovanna Mansueto, Fiorella D'Auria, Vitina Grieco, Gabriella Bianchino, Anna Sparano, Antonia Zonno, Rosa Lerose, Grazia Sanpaolo, Antonietta Falcone

Research output: Contribution to journalArticlepeer-review

Abstract

This was a retrospective, comparative study focused on the extended follow-up of 192 transfusion-dependent patients with myelodysplastic syndromes treated (n. 83) or not treated (n. 109) with recombinant erythropoietin alpha (r-EPO) as single agent during the course of their disease. The results supported the safety of this treatment in the long term and also showed a significant survival advantage (median 52 months vs. 31 months, p<0.0095) in responding patients as compared to non-responding ones or to subjects never treated with r-EPO. At multivariate analysis, response to r-EPO maintained an independent prognostic value on OS.

Original languageEnglish
Pages (from-to)981-985
Number of pages5
JournalLeukemia Research
Volume34
Issue number8
DOIs
Publication statusPublished - Aug 2010

Keywords

  • Anemia
  • Darbepoetin
  • G-CSF
  • Myelodysplastic syndromes
  • Prognosis
  • Recombinant erythropoietin
  • Survival
  • Transfusion

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Response to recombinant erythropoietin alpha, without the adjunct of granulocyte-colony stimulating factor, is associated with a longer survival in patients with transfusion-dependent myelodysplastic syndromes'. Together they form a unique fingerprint.

Cite this